Does the mixed-lineage kinase 3 inhibitor URMC-099 facilitate microglial amyloid-β degradation?
URMC-099 reduced microglial inflammatory responses and facilitated phagolysosomal trafficking with associated Aβ degradation. These data demonstrate a new immunomodulatory role for URMC-099 to inhibit MLK and to induce microglial anti-inflammatory responses. Thus, URMC-099 may be developed further as a novel disease-modifying AD therapy.
EDLOS>8 hours and EDLOS<4 hours are not independently associated with mortality. A longer EDLOS is independently associated with longer IPLOS.